5-氧代万络 | 179175-15-6

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 中文名称: 5-氧代万络
• 英文名称: 4-(4-(methylsulfonyl)phenyl)-3-phenylfuran-2(5H)-one
• 英文别名: 2-(4-(Methylsulfonyl)Phenyl)-3-Phenylmaleic Anhydride；5-Keto Vioxx；3-(4-methylsulfonylphenyl)-4-phenylfuran-2,5-dione
• CAS: 179175-15-6
• 化学式: C₁₇H₁₂O₅S
• 分子量: 328.345
• InChiKey: LJZJWBAPABMSII-UHFFFAOYSA-N

物化性质

• 熔点：
  140-142 °C
• 沸点：
  573.0±50.0 °C(Predicted)
• 密度：
  1.414±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  85.9
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  3-(4-thiomethoxyphenyl)-4-phenylfuran-2,5.dione 在 间氯过氧苯甲酸 作用下， 以 二氯甲烷 为溶剂， 生成 5-氧代万络
  参考文献：
  名称：

  Synthesis and PGE2 production inhibition of 1H-furan-2,5-dione and 1H-pyrrole-2,5-dione derivatives

  摘要：

  3,4-Diphenyl-substituted 1H-furan-2,5-dione and 1H-pyrrole-2,5-dione derivatives were synthesized and evaluated for the inhibitory activities on LPS-induced PGE(2) production in RAW 264.7 macrophage cells. Both 1H-furan-2,5-dione and 1H-pyrrole-2,5-dione rings as main scaffolds were easily obtained using one of three synthetic methods. Among the compounds investigated, 1H-3-(4-sulfamoylphenyl)-4-phenyl-pyrrole-2,5-dione (6l) showed a strong inhibitory activity (IC50 = 0.61 mu M) of PGE(2) production. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.11.067

文献信息

• Stilbene derivatives useful as cyclooxygenase-2 inhibitors
  申请人：Merck Frosst Canada, Inc.

  公开号：US05849943A1

  公开（公告）日：1998-12-15

  The invention encompasses novel compounds of Formula Iuseful in the treatment of cyclooxygenase-2 mediated diseases. ##STR1## The invention also encompasses certain pharmaceuticalcompositions and methods for treatment of cyclooxygenase-2 mediated diseases comprising the use of compounds of Formula I.

  本发明包括用于治疗环氧合酶-2介导疾病的公式I新颖化合物。##STR1## 本发明还包括某些药物组合物和治疗方法，用于治疗包括使用公式I化合物的环氧合酶-2介导疾病。
• Synthesis of 3,4-Diarylsubstituted Maleic Anhydride/Maleimide via Unusual Oxidative Cyclization of Phenacyl Ester/Amide
  作者：Vijaya Raghavan Pattabiraman、Srinivas Padakanti、Venugopal Rao Veeramaneni、Manojit Pal、Koteswar Rao Yeleswarapu

  DOI：10.1055/s-2002-31901

  日期：——

  A simple and general method has been developed for the synthesis of 3,4-diarylsubstituted maleic anhydride and maleimide through tandem cyclization and oxidation reaction of phenacyl ester or amide. A wide variety of phenacyl esters or amides was treated with DBU under oxygen atmosphere to give the expected compounds in good to excellent yield. Mechanism of the reaction and application of the methodology

  开发了一种简单通用的方法，通过苯甲酰酯或酰胺的串联环化和氧化反应合成3,4-二芳基取代的马来酸酐和马来酰亚胺。多种苯甲酰酯或酰胺在氧气气氛下用 DBU 处理，得到预期的化合物，收率良好至极好。讨论了反应机理和方法学的应用。
• [EN] STILBENE DERIVATIVES USEFUL AS CYCLOOXYGENASE-2 INHIBITORS<br/>[FR] DERIVES DE STILBENE UTILISABLES COMME INHIBITEURS DE LA CYCLO-OXYGENASE 2
  申请人：MERCK FROSST CANADA INC.

  公开号：WO1996013483A1

  公开（公告）日：1996-05-09

  (EN) The invention encompasses novel compounds of Formula (I) useful in the treatment of cyclooxygenase-2 mediated diseases. The invention also encompasses certain pharmaceutical compositions and methods for treatement of cyclooxygenase-2 mediated diseases comprising the use of compounds of Formula (I).(FR) La présente invention concerne de nouveaux composés représentés par la formule (I) utilisables dans le cadre du traitement des maladies induites par la cyclo-oxygénase 2. L'invention concerne également certaines compositions pharmaceutiques ainsi que des méthodes de traitement des maladies induites par la cyclo-oxygénase 2 qui font usage des composés représentés par la formule (I).

  该发明涵盖了公式（I）的新化合物，可用于治疗环氧合酶-2介导的疾病。该发明还涵盖了某些药物组合物和治疗环氧合酶-2介导疾病的方法，其中包括使用公式（I）的化合物。
• Dosage forms of rofecoxib and related methods
  申请人：Tremeau Pharmaceuticals, Inc.

  公开号：US10945992B1

  公开（公告）日：2021-03-16

  The subject matter disclosed herein relates to novel doses and dosage forms of rofecoxib having a therapeutic benefit.

  本文公开的主题涉及具有治疗效果的罗非昔布的新剂量和剂型。
• Purified forms of rofecoxib, methods of manufacture and use
  申请人：Tremeau Pharmaceuticals, Inc.

  公开号：US10987337B2

  公开（公告）日：2021-04-27

  The subject matter disclosed herein relates to rofecoxib, also known as TRM-201 or RXB-201, its method of manufacture, and use. In certain aspects, the highly pure or substantially pure rofecoxib as provided herein has a favorable purity profile and is the active ingredient in a pharmaceutical composition that is administered to treat or prevent a number of conditions, including pain associated with a condition caused by a bleeding disorder.

  本文公开的主题涉及罗非昔布（又称 TRM-201 或 RXB-201）、其制造方法和用途。在某些方面，本文提供的高纯度或基本纯度的罗非昔布具有良好的纯度特征，是一种药物组合物中的活性成分，该药物组合物用于治疗或预防多种疾病，包括与出血性疾病引起的病症相关的疼痛。